# Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

> **NCT04458922** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Central Chondrosarcoma, Grade 2
- Central Chondrosarcoma, Grade 3
- Dedifferentiated Chondrosarcoma
- Metastatic Clear Cell Sarcoma of Soft Tissue
- Metastatic Primary Central Chondrosarcoma
- Unresectable Primary Central Chondrosarcoma

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography

## Key facts

- **NCT ID:** NCT04458922
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-05
- **Primary completion:** 2022-11-28
- **Final completion:** 2026-12-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04458922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04458922, "Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04458922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*